Clinical Trials Logo

Neuroendocrine Tumor, Malignant clinical trials

View clinical trials related to Neuroendocrine Tumor, Malignant.

Filter by:
  • None
  • Page 1

NCT ID: NCT03044977 Active, not recruiting - Clinical trials for Neuroendocrine Tumor, Malignant

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

Start date: May 7, 2017
Phase: Early Phase 1
Study type: Interventional

This study is designed to identify the best tolerated doses of [131]Iodine-MIBG and [90]Yttrium-DOTATOC when co-administered to treat midgut neuroendocrine tumors. These drugs (131I-MIBG, 90Y-DOTATOC) are radioactive drugs, known as radionuclide therapy. Currently, the safest and best tolerated doses of these drugs (when combined together) is unknown.

NCT ID: NCT02724540 Active, not recruiting - Liver Metastases Clinical Trials

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.